Management of relapses in patients with multiple sclerosis
pdf

Keywords

multiple sclerosis, neurological symptoms, disease modifying therapy, relapse.

How to Cite

Dzyak , L., & Tsurkalenko , O. (2018). Management of relapses in patients with multiple sclerosis. The Journal of Neuroscience, 6(1), 88-98. Retrieved from https://neuroscience.com.ua/index.php/journal/article/view/65

Abstract

The therapeutic possibilities and strategies for treating patients with exacerbations of multiple sclerosis (MS) based on literature data and on the own clinical observations was described in the article. A lot of clinical studies have shown that early onset and prolonged use of disease modifying therapy reduces the frequency and severity of relapses (relapse, exacerbation, exacerbation, attack or flare-up), defined as the spontaneous appearence of new or worsening of existing neurologic symptoms, and also delay the development of disability .

pdf

References

1. Repovic P., Lublin F.D. Treatment of multiple sclerosis exacerbations // Neurol. Clin. — 2011. — Vol. 29. — Р. 389-400.
2. Costello K., Halper J., Kalb R., Skutnik L., Rapp R. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. A consensus paper by the Multiple Sclerosis Coalition. — 2014 July.
3. Inusah S., Sormani M.P., Cofield S.S. et al. Assessing changes in relapse rates in multiple sclerosis // Mult. Scler. — 2010. — Vol. 16. — Р. 1414-1421.
4. Scalfari A., Neuhaus A., Degenhardt A. et al. The natural history of multiple sclerosis, a geographically based study
10: relapses and long-term disability // Brain. — 2010. — Vol. 133. — Р. 1914-1929.
5. Kalincik T., Buzzard K., Jokubaitis V. et al; MSBase Study Group. Risk of relapse phenotype recurrence in multiple sclerosis // Mult. Scler. — 2014. — Vol. 20. — Р. 1511-1522.
6. Ross A.P., Halper J., Harris C.J. Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective // Int. J. MS Care. — 2012. — Vol. 14. — Р. 148-159.
7. Thompson A.J., Kennard C., Swash M. et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS // Neurology. — 1989. — Vol. 39. — Р. 969-971.
8. Le Page E., Veillard D., Laplaud D. et al. Efficacy and safety of oral versus intravenous high-dose methylprednisolone in multiple sclerosis relapses, a randomized double blind trial (COPOUSEP). Poster presented at: 2014 Joint ACTRIMS− ECTRIMS Meeting; Septembe. Boston, MA. Abstract PS9.3. — 2014. — Р. 10-13
9. Grau- López L., Teniente-Serra A., Tintore M. et al. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses // Mult. Scler. — 2014.
10. Berkovich R. Treatment of acute relapses in multiple sclerosis // Neurotherapeutics. — 2013. — Vol. 10. — Р. 97-105.
11. Ehler J., Koball S., Sauer M. et al. Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with clinically isolated syndrome // Ther. Apher. Dial. — 2014. — Vol. 18. — Р. 489-496.
12. Durelli L., Cocito D., Riccio A. et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations //
Neurology. — 1986. — Vol. 36. — Р. 238-243.
13. Milligan N.M., Newcombe R., Compston D.A. A doubleblind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects // J. Neurol. Neurosurg. Psychiatry. — 1987. — Vol. 50. — Р. 511-516.
14. Thrower B.W. Relapse management in multiple sclerosis // Neurologist. — 2009. — 15 (1). — P. 1-5.
15. Beck R.W., Cleary P.A. Optic neuritis treatment trial: one-year follow-up re-sults // Arch. Ophthalmol. — 1993. — Vol. 111. — Р. 773-775.